Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804634 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
A Phase 2 study of Refractory and/or Relapsed Metastatic Solid Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT01804634 is a Phase 2 study of Refractory and/or Relapsed Metastatic Solid Tumors that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 60 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT01804634, a Phase 2 study of Refractory and/or Relapsed Metastatic Solid Tumors, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Tacrolimus
- RADIATION low dose total body irradiation
Study Locations (3)
New York
- Albert Einstein College of Medicine, Children's Hospital at Montefiore - The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital - Valhalla
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-03-27 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804634
The ClinicalTrials.gov registry entry for NCT01804634 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory and/or Relapsed Metastatic Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01804634 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Maryland.
Frequently Asked Questions
What is clinical trial NCT01804634 about?
NCT01804634 is a clinical study titled "Reduced Intensity Haploidentical BMT for High Risk Solid Tumors". The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
What is the current status of trial NCT01804634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2013-03-27. Estimated completion is 2030-01.
What conditions does trial NCT01804634 study?
This clinical trial studies the following conditions: Refractory and/or Relapsed Metastatic Solid Tumors.
What interventions are being tested in trial NCT01804634?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Melphalan (DRUG), Tacrolimus (DRUG), low dose total body irradiation (RADIATION).
Who is sponsoring clinical trial NCT01804634?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01804634 being conducted?
This trial has 3 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.